Advertisement

Improving the quality of care in the molecular era for children and adolescents with medulloblastoma

  • T. de Rojas
  • M. Puertas
  • F. Bautista
  • I. de Prada
  • M. Á. López-Pino
  • B. Rivero
  • C. Gonzalez-San Segundo
  • M. Gonzalez-Vicent
  • A. Lassaletta
  • L. Madero
  • L. MorenoEmail author
Research Article
  • 47 Downloads

Abstract

Purpose

Elevated mortality and morbidity rates persist in pediatric patients with medulloblastoma. We present a clinical audit of a real-world cohort of patients in search for pragmatic measures to improve their management and outcome.

Methods/patients

All pediatric patients with medulloblastoma treated between 2003 and 2016 at a Spanish reference center were reviewed. In the absence of internationally accepted quality indicators (QIs) for pediatric CNS tumors, diagnostic, therapeutic, survival, and time QIs were defined and assessed.

Results

Fifty-eight patients were included, 24% were younger children (< 3 years), 36% high risk (anaplastic, metastasis, or surgical residue > 1.5 cm2), and 40% standard risk. Five-year OS was 59.2% (95% CI 47–75); 5-year PFS 36.4% (95% CI 25–53). Five main areas of quality assurance were identified: diagnosis, global strategy, frontline treatment modalities, outcomes, and long-term and end-of-life care. A set of 34 QIs was developed and applied. Lack of central pathology review, delay in the incorporation of novel molecular markers, and absence of a neurocognitive and quality-of-life evaluation program were some of the audit findings.

Conclusions

This real-world research study resulted in the development of a pragmatic set of QIs, aimed to improve clinical audits and quality of care given to children and adolescents with medulloblastoma. We hope that our findings will serve as a reference to further develop a quality assurance system with specific QIs for pediatric CNS tumors in the future and that this will ultimately improve the survival and quality of life of these patients.

Keywords

Medulloblastoma CNS tumors Childhood Quality assurance Quality of care Real-world studies 

Notes

Acknowledgements

Teresa de Rojas’ work as a fellow at EORTC Headquarters was supported by a grant from Fonds Cancer (FOCA).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical statement

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments and comparable ethical standards.

Informed consent

Due to the retrospective nature of the study, formal consent was not required.

Supplementary material

12094_2019_2101_MOESM1_ESM.pdf (246 kb)
Supplementary material 1 (PDF 245 kb)
12094_2019_2101_MOESM2_ESM.pdf (33 kb)
Supplementary material 2 (PDF 33 kb)
12094_2019_2101_MOESM3_ESM.pdf (112 kb)
Supplementary material 3 (PDF 112 kb)

References

  1. 1.
    Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15:35–47.CrossRefGoogle Scholar
  2. 2.
    Massimino M, Biassoni V, Gandola L, Garrè ML, Gatta G, Giangaspero F, et al. Childhood medulloblastoma. Crit Rev Oncol Hematol. 2016;105:35–51.CrossRefGoogle Scholar
  3. 3.
    Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LAG, Eheman C, et al. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103:714–36.  https://doi.org/10.1093/jnci/djr077.CrossRefGoogle Scholar
  4. 4.
    Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29:1408–14.  https://doi.org/10.1200/JCO.2009.27.4324.CrossRefGoogle Scholar
  5. 5.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.CrossRefGoogle Scholar
  6. 6.
    Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog—subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J Clin Oncol. 2015;33:2646–54.CrossRefGoogle Scholar
  7. 7.
    Gajjar AJ, Robinson GW. Medulloblastoma-translating discoveries from the bench to the bedside. Nat Rev Clin Oncol. 2014;11:714–22.CrossRefGoogle Scholar
  8. 8.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:547.CrossRefGoogle Scholar
  9. 9.
    Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–25.CrossRefGoogle Scholar
  10. 10.
    Dufour C, Beaugrand A, Pizer B, Micheli J, Aubelle MS, Fourcade A, et al. Metastatic medulloblastoma in childhood: chang’s classification revisited. Int J Surg Oncol. 2012;2012:245385.Google Scholar
  11. 11.
    Institute NC. Common Terminology Criteria for Adverse Events v4.3. NCI, NIH, DHHS. 2010.Google Scholar
  12. 12.
    Pérez-Albert P, de Rojas T, Rey L, Hernández-Martín Á, Ruano D, Madero L. Tumor predisposition syndromes: the challenge of de novo mutations. Pediatr Blood Cancer. 2017;2:6882.  https://doi.org/10.1002/pbc.26882.Google Scholar
  13. 13.
    Grill J, Sainte-Rose C, Jouvet A, Gentet JC, Lejars O, Frappaz D, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 2005;6:573–80.CrossRefGoogle Scholar
  14. 14.
    Dhall G, Grodman H, Ji L, Sands S, Gardner S, Dunkel IJ, et al. Outcome of children less than 3 years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. Pediatr Blood Cancer. 2008;50:1169–75.CrossRefGoogle Scholar
  15. 15.
    Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol. 2012;30:3187–93.  https://doi.org/10.1200/JCO.2011.39.8719.CrossRefGoogle Scholar
  16. 16.
    Gandola L, Massimino M, Cefalo G, Solero C, Spreafico F, Pecori E, et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol. 2009;27:566–71.CrossRefGoogle Scholar
  17. 17.
    Jakacki RI, Burger PC, Zhou T, Holmes EJ, Kocak M, Onar A, et al. Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a children’s oncology group phase I/II study. J Clin Oncol. 2012;30:2648–53.CrossRefGoogle Scholar
  18. 18.
    Kowalczyk J, Samardakiewicz M, Kowalewska-Bajor M, Pomaska EA, Fitzgerald E ES. European Standards of Care for Children with Cancer. 2011. http://www.siope.eu/wp-content/uploads/2013/09/European_Standards_final_2011.pdf.
  19. 19.
    Ubago Otero E, Carrillo Ridao C, Pérez Graña B. Unidades asistenciales del cáncer en la infancia y adolescencia. http://www.aspanoa.org/files/CancerInfantil_EyR.pdf. Accessed 6 Apr 2018.
  20. 20.
    Bautista F, Fioravantti V, de Rojas T, Carceller F, Madero L, Lassaletta A, et al. Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update. Cancer Med. 2017;61:2606–24.CrossRefGoogle Scholar
  21. 21.
    From the American Academy of Pediatrics. Standards for pediatric cancer centers. Section on hematology/oncology. Pediatrics. 2014;134:410–4.CrossRefGoogle Scholar
  22. 22.
    NICE-National Institute for Health and Care Excellence. Standards and Indicators. NICE; 2018. https://www.nice.org.uk/standards-and-indicators. Accessed 18 Apr 2018.
  23. 23.
    NHS. The main components of clinical governance. 2018. https://www.uhb.nhs.uk/clinical-governance-components.htm. Accessed 18 Apr 2018.
  24. 24.
    Knops RRG, Hulscher MEJL, Hermens RPMG, Hilbink-Smolders M, Loeffen JL, Kollen WJW, et al. High-quality care for all children with cancer. Ann Oncol. 2012;23:1906–11.  https://doi.org/10.1093/annonc/mdr601.CrossRefGoogle Scholar
  25. 25.
    Vlayen J, Vrijens F, Devriese S, Beirens K, Van Eycken E, Stordeur S. Quality indicators for testicular cancer: a population-based study. Eur J Cancer. 2012;48:1133–40.CrossRefGoogle Scholar
  26. 26.
    Bradley NME, Robinson PD, Greenberg ML, Barr RD, Klassen AF, Chan YL, et al. Measuring the quality of a childhood cancer care delivery system: quality indicator development. Value Heal. 2013;16:647–54.CrossRefGoogle Scholar
  27. 27.
    de Rojas T, Bautista F, Flores M, Igual L, Rubio R, Bardón E, et al. Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care. J Neurooncol. 2018;137:205–13.CrossRefGoogle Scholar
  28. 28.
    Peris Bonet R, Felipe García S, Valero Poveda S PRE. Cáncer infantil en España. Estadísticas 1980–2014. Registro Español de Tumores Infantiles (RETI-SEHOP). Valencia; 2015. http://www.uv.es/rnti/pdfs/INFORME_1980–2014.pdf.
  29. 29.
    Igual Estellés L, Berlanga Charriel P, Cañete Nieto A. Medulloblastoma: improved survival in recent decades. Unicentric experience. An Pediatr (Barc). 2017;86:4–10.CrossRefGoogle Scholar
  30. 30.
    Moxon-Emre I, Bouffet E, Taylor MD, Laperriere N, Scantlebury N, Law N, et al. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. J Clin Oncol. 2014;32:1760–8.CrossRefGoogle Scholar
  31. 31.
    Palmer SL, Armstrong C, Onar-Thomas A, Wu S, Wallace D, Bonner MJ, et al. Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study. J Clin Oncol. 2013;31:3494–500.CrossRefGoogle Scholar
  32. 32.
    Fouladi M, Gilger E, Kocak M, Wallace D, Buchanan G, Reeves C, et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol. 2005;23:7152–60.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Authors and Affiliations

  • T. de Rojas
    • 1
  • M. Puertas
    • 2
  • F. Bautista
    • 3
  • I. de Prada
    • 4
  • M. Á. López-Pino
    • 5
  • B. Rivero
    • 6
  • C. Gonzalez-San Segundo
    • 7
  • M. Gonzalez-Vicent
    • 3
  • A. Lassaletta
    • 3
  • L. Madero
    • 3
    • 8
  • L. Moreno
    • 3
    • 8
    Email author
  1. 1.Medical DepartmentEuropean Organisation for Research and Treatment of Cancer (EORTC)BrusselsBelgium
  2. 2.Faculty of MedicineUniversidad Autónoma de MadridMadridSpain
  3. 3.Pediatric Hematology, Oncology and Stem Cell DepartmentHospital Infantil Universitario Niño JesúsMadridSpain
  4. 4.Pathology DepartmentHospital I.U. Niño JesúsMadridSpain
  5. 5.Pediatric Radiology DepartmentHospital I.U. Niño JesúsMadridSpain
  6. 6.Pediatric Neurosurgery DepartmentHospital I.U. Niño JesúsMadridSpain
  7. 7.Radiation Oncology DepartmentHospital G.U. Gregorio MarañónMadridSpain
  8. 8.Instituto de Investigación Sanitaria La PrincesaMadridSpain

Personalised recommendations